DEA maintains Schedule I classification for psilocybin and MDMA through Q3 2026.

Predicted 2026-07-17 · Resolves 2026-08-16 · regulation · USA

90%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

The DEA (the US drug enforcement agency) places drugs into categories called schedules; Schedule I means a drug is considered to have no accepted medical use and high abuse potential. Both MDMA and psilocybin will stay in that most restrictive category through at least September 2026. No official government paperwork to change that is currently in motion.

Resolution rule: YES if, as of 2026-08-16, both psilocybin and MDMA remain listed in Schedule I of the Controlled Substances Act. Checked via the DEA scheduling list (deadiversion.usdoj.gov) and federalregister.gov for any final rescheduling rule. Any published final rule moving either substance out of Schedule I before the check date resolves NO.

DEA has issued no proposed rescheduling rule for either substance; final rescheduling would require a published Federal Register action. None is in the pipeline for the near term.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →